Vir Biotechnology
VIR
11.52
-0.08
-0.69%
Vir Biotechnology
US · VIR
#2824 by market cap
Listed 2019
11.52
-0.08
-0.69%
Live - 5344 symbols - heartbeat 539s ago
· 2026-10-08 08:30
Pre-market
11.85
+2.86%
After-hours
11.52
0.00%
Overnight
11.64
+1.04%
- Market cap
- 1.95B
- P/E (TTM)i
- -6.51
- P/Bi
- 1.98
- EPSi
- -3.16
- Div yieldi
- 0.00%
- 52W posi
- 94%
Reader sentiment
Are you bullish or bearish on VIR?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.25, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -7.61% YoY
Margins
- Gross margin
- 99.96%
- Operating margin
- -720.85%
- Net margin
- -658.43%
Key ratios & quality
- Altman Z-Scorei
- 2.25
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.67M | 8.09M | 76.37M | 1.10B | 1.62B | 86.18M | 74.21M | 68.56M |
| Gross profit | -- | 711.00K | 67.25M | 1.02B | 1.43B | 36.73M | 62.87M | 66.49M |
| Selling & admin expenses | 29.13M | 37.60M | 70.94M | 160.79M | 161.76M | 174.44M | 119.03M | 92.07M |
| Research & development | 100.23M | 148.47M | 302.41M | 448.01M | 474.65M | 579.72M | 506.50M | 455.97M |
| Operating profit | -118.69M | -177.98M | -296.98M | 420.75M | 833.07M | -670.75M | -552.17M | -479.51M |
| Pretax profit | -116.36M | -174.53M | -298.61M | 549.80M | 754.28M | -628.19M | -523.11M | -437.77M |
| Tax | -480.00K | 154.00K | 54.00K | 21.22M | 238.44M | -13.08M | -1.15M | 217.00K |
| Net profit | -115.88M | -174.68M | -298.67M | 528.58M | 515.84M | -615.12M | -521.96M | -437.99M |
| Basic EPS | -1 | -6 | -3 | 4 | 4 | -5 | -4 | -3 |
| Diluted EPS | -1.20 | -5.76 | -2.51 | 3.96 | 3.83 | -4.59 | -3.83 | -3.16 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.03M | 1.21M | 240.00K | 64.07M | -29.00K | 238.95M |
| Gross profit | -- | 1.02M | -54.00K | 63.73M | -- | 238.94M |
| Selling & admin expenses | 23.94M | 22.28M | 22.23M | 23.62M | 23.34M | 30.20M |
| Research & development | 118.65M | 97.51M | 151.46M | 88.35M | 108.92M | 135.28M |
| Operating profit | -139.56M | -118.59M | -173.44M | -47.92M | -132.29M | 73.47M |
| Pretax profit | -120.95M | -110.79M | -162.97M | -43.06M | -125.53M | 80.26M |
| Tax | 16.00K | 170.00K | 168.00K | -137.00K | 170.00K | 179.00K |
| Net profit | -120.97M | -110.96M | -163.14M | -42.92M | -125.70M | 80.08M |
| Basic EPS | -1 | -1 | -1 | 0 | -1 | 0 |
| Diluted EPS | -0.88 | -0.80 | -1.17 | -0.31 | -0.85 | 0.47 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 117.78M | 403.00M | 772.37M | 1.56B | 2.52B | 1.59B | 1.04B | 514.08M |
| Cash & ST investments | 98.44M | 383.44M | 736.86M | 708.15M | 2.40B | 1.52B | 905.35M | 467.02M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 191.60M | 512.07M | 918.76M | 1.95B | 2.80B | 1.92B | 1.40B | 1.00B |
| Total current liabilities | 39.91M | 59.21M | 99.06M | 341.24M | 511.03M | 175.41M | 119.66M | 92.82M |
| Short-term debt | -- | 237.00K | 3.63M | 3.93M | 4.14M | 12.87M | 7.75M | 8.80M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 370,773,000.00 | 88,129,000.00 | 201,909,000.00 | 522,419,000.00 | 724,125,000.00 | 328,824,000.00 | 248,428,000.00 | 237,547,000.00 |
| Total equity | -179.18M | 423.94M | 716.85M | 1.43B | 2.08B | 1.59B | 1.15B | 765.28M |
| Retained earnings | -193.84M | -368.52M | -667.18M | -138.60M | 377.24M | -237.82M | -759.78M | -1.20B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 932.21M | 735.71M | 545.68M | 514.08M | 522.99M | 573.74M |
| Cash & ST investments | 801.66M | 606.02M | 506.51M | 467.02M | 476.30M | 532.73M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.31B | 1.19B | 1.02B | 1.00B | 1.03B | 1.21B |
| Total current liabilities | 137.29M | 105.00M | 75.22M | 92.82M | 73.56M | 94.96M |
| Short-term debt | 7.93M | 8.83M | 8.96M | 8.80M | 8.94M | 9.14M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 263,908,000.00 | 245,060,000.00 | 223,355,000.00 | 237,547,000.00 | 212,820,000.00 | 232,313,000.00 |
| Total equity | 1.04B | 947.47M | 796.10M | 765.28M | 812.77M | 982.49M |
| Retained earnings | -880.75M | -991.71M | -1.15B | -1.20B | -1.32B | -1.24B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -94.10M | -129.63M | -190.94M | -47.59M | 1.66B | -778.79M | -446.35M | -391.78M |
| Depreciation & amortization | 2.76M | 4.52M | 5.44M | 5.81M | 6.78M | 19.45M | 14.56M | 11.68M |
| Free cash flow | -102.29M | -138.57M | -197.49M | -69.41M | 1.60B | -800.36M | -453.65M | -396.61M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 126.41M | 529.91M | 85.21M | 28.46M | -- | -- | -- |
| Ending cash balance | 59.36M | 122.82M | 451.49M | 363.42M | 867.97M | 261.29M | 318.70M | 241.07M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -78.12M | -120.22M | -167.57M | -25.88M | -132.39M | 123.33M |
| Depreciation & amortization | 2.87M | 2.92M | 3.00M | 2.90M | 2.81M | 2.80M |
| Free cash flow | -79.75M | -122.76M | -167.89M | -26.22M | -132.78M | 123.29M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -- | -- | 162.35M | 75.58M |
| Ending cash balance | 368.00M | 306.28M | 179.26M | 241.07M | 283.04M | 287.60M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -142.74 | -52.36 | 49.20 | 29.39 | -33.53 | -38.09 | -45.73 |
| ROA %i | -52.26 | -49.65 | -41.75 | 36.80 | 21.69 | -26.06 | -31.46 | -36.47 |
| ROIC %i | -- | -147.53 | -47.18 | 44.82 | 26.31 | -35.72 | -40.07 | -44.50 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -30.01 | -9.08 | -7.75 |
| EBIT margin %i | -13,674.19 | -25,032.21 | -441.64 | 38.71 | 52.71 | -1,732.68 | -866.67 | -720.85 |
| FCF / sales %i | -- | -- | -- | -- | 100.93 | -- | -- | -- |
| Current ratioi | 2.95 | 6.81 | 7.80 | 4.58 | 4.93 | 9.05 | 8.71 | 5.54 |
| Quick ratioi | 2.47 | 6.48 | 7.44 | 4.34 | 4.70 | 8.68 | 7.57 | 5.03 |
| Debt / assetsi | 0.00 | 0.05 | 7.64 | 7.04 | 4.57 | 6.49 | 7.00 | 9.76 |
| LT debt / equityi | -- | -- | 9.28 | 9.33 | 5.96 | 7.02 | 7.84 | 11.64 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | 667.05 | 977.90 | 1,205.09 | -16.26 | -61.16 | -65.22 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -44.59 | -46.22 | -49.06 | -45.73 | -47.69 | -26.08 |
| ROA %i | -37.25 | -38.45 | -39.69 | -36.47 | -37.95 | -20.91 |
| ROIC %i | -45.60 | -45.69 | -47.69 | -44.50 | -45.29 | -25.56 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -4,276.31 | -4,153.92 | -3,937.05 | -720.85 | -730.07 | -92.60 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.79 | 7.01 | 7.25 | 5.54 | 7.11 | 6.04 |
| Quick ratioi | 5.84 | 5.77 | 6.73 | 5.03 | 6.48 | 5.61 |
| Debt / assetsi | 7.35 | 8.57 | 9.83 | 9.76 | 9.32 | 7.68 |
| LT debt / equityi | 8.45 | 9.86 | 11.46 | 11.64 | 10.66 | 8.56 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Business of powering the immune system to transform lives by discovering and developing medicines100.00%
Quote time 2026-10-08 08:30:00 · For reference only, not investment advice and not tailored to your situation.